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Recessive dystrophic epidermolysis bullosa (RDEB) is a severe mechanobullous 
disease characterized on the molecular level by mutations in the COL7A1 
gene, which encodes the keratinocyte-secreted protein type VII collagen, and 
clinically by an increased risk of developing squamous-cell carcinoma (SCC). 
The consequences of SCC development can be significant—55% of patients 
with the Hallopeau–Siemens subtype of RDEB die from metastatic SCC by 
age 40 (Fine et al., 1999). Thus, patients with RDEB require close monitoring 
for development and treatment of potential life-threatening cancers. A recent 
paper by Ortiz-Urda et al. (2005) reported, as part of a broader work describing 
the role of Ras and type VII collagen in epidermal tumorigenesis, that in an 
analysis of 10 patients with RDEB who developed SCC, all 10 displayed type 
VII collagen within their tumors. The results suggested that only a subset 
of patients who express type VII collagen develop SCC. These findings led 
Pourreyron and colleagues (2007, this issue) to attempt to confirm the results. They studied a discrete subset of 11 
patients with RDEB (8 with the Hallopeau-Siemens subtype) who developed 17 SCCs. Of 10 patients (16 tumors), 8 
demonstrated type VII collagen expression. In 2 patients (3 tumors) no type VII collagen was detected. The 2 patients 
and their tumors without type VII collagen detection exhibited compound heterozygous nonsense mutations within 
the region encoding the NC1 domain of the COL7A1 gene. Through the following questions we delve into this paper 
in greater detail. For brief answers please refer to http://network.nature.com/group/jidclub.
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QUESTIONS
1. Why is the NCI domain crucial to SCC development according to Ortiz-Urda et al.?
2.  Is the hypothesis being tested that patients with dystrophic EB require the presence of type VII collagen for development  
of SCC?
3. Why were immunofluorescence and immunoblotting used in this study?
4. What controls were used?
5. Do the findings of this study contradict the findings of Ortiz-Urda et al.?
6. What clinical implications does the article suggest?
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